Skip to content Skip to footer
Subscribe Now
Pfizer New
NEWS

Pfizer Reports Positive P-III Results for LITFULO in Nonsegmental Vitiligo (NSV)

Shots: Pfizer reported positive topline results from the pivotal P-III TRANQUILLO and TRANQUILLO 2 studies evaluating LITFULO (ritlecitinib) in pts. with NSV. Both studies (n=2,174 pts) met their co-primary endpoints, demonstrating statistically significant improvements in facial and total body repigmentation vs. PBO at 52 wks. across 271 sites globally TRANQUILLO (n=607, ≥12yrs.) evaluated 50mg LITFULO and TRANQUILLO…
July 31, 2026

Read more

NEWS

NIPRO Receives FDA 510(k) Clearance for ELISIO-HX Dialyzer for Expanded Hemodialysis in the US

Shots: NIPRO CORPORATION received US FDA 510(k) clearance for its ELISIO-HX dialyzer, enabling the US commercialization of HDs (Hemodialysis powered by super high-flux membrane). The clearance became effective on July 28, 2026 ELISIO-HX features NIPRO’s proprietary super high-flux membrane technology, designed to enhance the removal of larger middle-molecule uremic toxins while maintaining albumin retention. The…
July 31, 2026

Read more

TOP 20

Top 20 Immunology Companies of 2026 

Shots:  AbbVie led the global immunology market with $30.4B in immunology revenue in 2025, followed by Sanofi ($19.08B) and Johnson & Johnson ($15.72B). Continued demand for biologics and targeted therapies across autoimmune and inflammatory diseases supported strong commercial performance among leading companies.   The global immunology market, valued at $108.4B in 2024, is projected to…
July 17, 2026

Read more

INSIGHTS+ TOP 20

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2006-2025) 

Shots:  PharmaShots' latest report chronicles the transformation of the global biopharma industry from 2006–2025, highlighting how innovation, strategic M&A, AI adoption, and evolving commercialization strategies have reshaped the competitive landscape while companies navigated patent cliffs, pricing pressures, and shifting market dynamics.   The report tracks the rise and fall of leading biopharma companies over two decades driven by…
July 10, 2026

Read more

TOP 20

Top 20 Vaccines of 2026

Shots:   The global vaccine market, valued at $72.8B in 2025 and projected to reach $115.8B by 2033, continues to benefit from expanding immunization coverage, growing awareness of infectious disease prevention, and innovation across RSV, pneumococcal, HPV, and mRNA vaccines. Pfizer’s Prevnar Family led the market with $6.49B in revenue, followed by Merck’s Gardasil/Gardasil 9 ($5.23B)…
June 26, 2026

Read more

NEWS

AbbVie to Acquire Apogee Therapeutics for ~$10.9B

Shots: AbbVie entered into a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, at a total equity value of approximately $10.9B. The transaction is expected to close in Q3’26, subject to shareholder and regulatory approvals The acquisition strengthens AbbVie’s immunology portfolio by adding Apogee’s clinical-stage pipeline focused on inflammatory and immunological…
June 22, 2026

Read more

NEWS

Murj Expands Commercial Operations Across Australia and New Zealand for Cardiac Device Management Solutions

Shots: Murj announced the commercial launch of its cardiac device management platform in Australia and expanded availability in New Zealand, following its participation at the CSANZ/HRS Advances in Pacing and Conduction System Pacing Summit in Melbourne The expansion enables healthcare providers across the region to access Murj’s cloud-native solutions for cardiac implantable electronic device (CIED)…
June 22, 2026

Read more

NEWS

BioArctic and Lilly Sign Research and Collaboration Agreement ~$800M to Advance Neurodegenerative Disease Therapy

Shots: BioArctic entered a research and collaboration agreement with Eli Lilly and Company to develop a potential treatment for neurodegenerative diseases by combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate Under the agreement, BioArctic will generate a new drug candidate incorporating its BrainTransporter platform, while Lilly will assume full responsibility for the…
June 22, 2026

Read more

NEWS

Insilico Medicine and SK Biopharmaceuticals Sign AI-Driven Drug Discovery Deal Worth Up to $2.5B for Neuroimmune Disorders

Shots: Insilico Medicine and SK Biopharmaceuticals entered a research and development collaboration to discover AI-enabled therapies for neuroimmune disorders of the central nervous system (CNS), including neuroinflammatory, neurodegenerative, and rare neurological diseases Under the agreement, Insilico will utilize its proprietary Pharma.AI platform, covering target validation, generative chemistry, and molecule optimization, alongside its preclinical drug discovery…
June 22, 2026

Read more

NEWS

MoonLake Reports Positive Week 52 P-III (VELA) Data for Sonelokimab in Hidradenitis Suppurativa (HS)

Shots: MoonLake Immunotherapeutics reported positive 52 Wks. (n=396) results from the P-III (VELA-1) and (VELA-2) studies, demonstrating durable efficacy of sonelokimab in adults with moderate-to-severe HS At Week 52, 67.2% of pts. achieved HiSCR75, 33.1% achieved HiSCR100, and 26.0% reached inflammatory remission (IHS4-100). Sonelokimab also showed substantial improvements in quality of life and pain reduction,…
June 22, 2026

Read more

Load more